First-in-human Study of Simmitinib, a Novel Tyrosine Kinase Inhibitor Targeting FGFR1-3, KDR and CSF-1R.
Sheng Yang,Yanqiao Zhang,Mingjun Zhang,Yongzhong Wu,Yongsheng Li,Feng Wang,Xin Tian,Suxia Luo,Yuping Sun,Linlin Wang,Jiancheng Li,Da Jiang,Mingxia Wang,Yunchao Huang,Huaqiu Shi,Haiyu Yang,Xiaowen Liu,Wei Ji,Weiqing Pu,Yuankai Shi
DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.3109
IF: 45.3
2024-01-01
Journal of Clinical Oncology
Abstract:3109 Background: Simmitinib, a potent tyrosine kinase inhibitor targeting FGFR1-3, KDR and CSF-1R, was evaluated in a phase I study in patients with advanced solid tumors. Methods: The study included dose-escalation cohorts and dose-expansion cohorts. In the dose-escalation cohorts, patients received simmitinib at doses from 1 to 9 mg orally. The DLT observation period consisted of a single dose over 7 days and multiple doses over 28 consecutive days. Patients were assessed for safety, pharmacokinetics, and efficacy. Results: As of October 31, 2023, 98 patients with a median age of 60 years (range 27-70) were enrolled. 24 patients were enrolled in the dose-escalation cohorts and 74 in the dose-expansion cohorts. One DLT was reported in the 9 mg group (grade 3 hypertension lasted for more than 3 days). The maximum tolerated dose (MTD) was not achieved. Furthermore, 4 mg QD, 6 mg QD and 6 mg 3 weeks on 1 week off dosing regimens were employed for expansion. Treatment-related adverse events (TRAEs) were reported in 88 patients (89.8%); detailed TRAEs of any grade occurring in ≥ 10% patients are listed in the table below. The incidence of TRAEs in the 6 mg 3 weeks on 1 week off group was the lowest among all the dosing regimens, with TRAEs any grade and grade ≥ 3 reported in 18 patients (66.7%) and 4 patients (14.8%), respectively. Of 56 patients with pretreated esophageal squamous carcinoma, the ORR was 16.1% (95% CI, 7.6-28.3%) with DCR of 46.4% (95% CI, 33.0-60.3%) and median PFS of 5.7 months (95% CI, 3.5-6.7); the ORRs for 4 mg QD, 6 mg QD, 6 mg 3 weeks on 1 week off, and 9 mg QD groups were 0 (0/6), 13.6% (3/22, 95% CI, 2.9-34.9%), 19.2% (5/26, 95% CI, 6.6-39.4%) and 50.0% (1/2, 95% CI, 1.3-98.7%), respectively. Based on the results of safety and efficacy, 6 mg 3 weeks on 1 week off was selected as recommended phase Ⅱ dose (RP2D). Statistical analysis using a power model for ln-transformed exposures (Cmax and AUC0-∞) suggested dose proportionality from 1 to 9 mg (95% CI of the slope estimate included the value of 1). Higher copy numbers of FGF3, FGF4, or FGF19 appeared to be associated with durable disease control in preliminary biomarker analysis, and further exploration is ongoing. Conclusions: Simmitinib showed manageable toxicity in the study and encouraging activity in esophageal squamous carcinoma. Accordingly, 6 mg 3 weeks on 1 week off was recommended for phase Ⅱ trials. Clinical trial information: NCT04058587 . [Table: see text]